Bcl-2 can both promote and attenuate tumorigenesis. Although the former function is relatively well characterized, the mechanism of the latter remains elusive. We report here that enforced Bcl-2 expression in MCF7 cells stabilizes p53, induces phosphorylation of p53 serine 15 (p53pSer15) and inhibits MCF7 cell growth. Consistent with p53 Ser15 being a target of ataxia telangiectasia mutated protein(ATM)/ATR (ATM-and rad3-related) in the DNA damage response, Bcl-2 activates ATM by inducing ATM Ser1981 phosphorylation, which is accompanied with the phosphorylaton of two additional ATM substrates, Chk2 Thr68 and H2AX Ser139. Downregulation of ATM using a specific small interference RNA fragment (ATMRNAi) abolished Bcl-2-induced p53pSer15 and Bcl-2-mediated growth inhibition of MCF7 cells. Ectopic expression of a dominant-negative p53 mutant, p53175H, partially rescued this growth inhibition. Taken together, these observations demonstrate the contribution of ATM-p53 function to Bcl-2-mediated inhibition of MCF7 cell growth, indicating an ATM-mediated surveillance system for regulating Bcl-2 overexpression. Consistent with this concept, we found that MCF7 cells express Bcl-2 heterogeneously with 34.5% of cells being Bcl-2 negative. In general, Bcl-2-positive MCF7 cells proliferate slower than those of Bcl-2 negative. Thus, we provide evidence suggesting that activation of ATM suppresses Bcl-2-induced tumorigenesis, and that attenuation of ATM function may be an important event in breast cancer progression.
Introduction
Bcl-2 overexpression was first observed in human follicular lymphoma as a consequence of the translocation of t(14;18) (Tsunimoto et al., 1984; Bakhshi et al., 1985; Cleary et al., 1986) and has since been detected in many other cancers (Kirkin et al., 2004) . This agrees well with the overwhelming evidence showing that Bcl-2 contributes to the tumorigenesis by inhibiting apoptosis. Bcl-2 functions in maintaining the membrane integrity of the mitochondria (Kharbanda et al., 1997; Kluck et al., 1997; Yang et al., 1997) and endoplasmic reticulum (ER)-mediated calcium homeostasis (Scorrano et al., 2003) , thereby inhibiting apoptosis. Recent developments also reveal that Bcl-2 reduces the capacity of cells to repair their damaged DNA, leading to genomic instability, which is a major force in tumorigenesis (Saintigny et al., 2001; Youn et al., 2005) .
However, Bcl-2 has also been reported to be associated with activities or processes that suppress tumorigenesis. Overexpression of Bcl-2 in leukemia cells, lymphocytes and other mammalian cells inhibits cellcycle entry (Pietenpol et al., 1994; Brady et al., 1996; Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., 1996; Vairo et al., 1996; Huang et al., 1997) . In a mouse mammary tumor model, Bcl-2 expression delays tumor progression (Murphy et al., 1999) , consistent with clinical observations showing that high levels of Bcl-2 protein are associated with favorable prognosis in breast cancer patients (Jager et al., 2002) . Additionally, co-expression of Bcl-2 specifically suppressed c-Myc-induced hepatocarcinoma in transgenic mice (de La Coste et al., 1999) . Although these observations demonstrate Bcl-2-associated tumor suppression, the mechanisms responsible for this activity is largely unknown. One possible means to reconcile Bcl-2's pro-and anti-tumorigenesis activities is the existence of a surveillance system to regulate Bcl-2-induced oncogenesis.
The tumor suppressor p53 plays a major role in the surveillance of oncogenic activities. Expression of oncogenic Ras, c-Myc, E1A, E2F1, v-Abl and/or bcatenin in normal cells activates p53, at least in part, via the p14/p19 ARF tumor suppressor (Serrano et al., 1997;  de Stanchina et al., 1998; Palmero et al., 1998; Zindy et al., 1998; Cong et al., 1999; Dimri et al., 2000; Damalas et al., 2001) . In contrast, in colorectal cancer, expression of b-catenin induces p53 stabilization independently of p14/p19 ARF (Damalas et al., 1999) . However, exactly how oncogenic or hyperproliferation signals activate the p53 tumor surveillance system remains largely elusive.
Ataxia telangiectasia mutated protein (ATM) plays an essential role in the cellular DNA damage response that maintains genome stability (Shiloh, 2003) . Patients with A-T display defects in DNA damage response and are predisposed to cancer (Shiloh, 2003) . Ataxiatelangiectasia mutated protein exists as an inactive dimer and DNA double-stranded breaks (DSBs) induce ATM activation by intermolecular autophosphorylation of Ser1981 of human ATM, leading to the generation of active ATM monomers (Bakkenist and Kastan, 2003) . Ataxia telangiectasia mutated protein activation is facilitated by interaction with the MRE11-RAD50-NBS1 complex that functions in DNA damage repair (Lee and Paull, 2004) . Activated ATM sets in motion a series of downstream events, including phosphorylation of Ser139 of histone H2AX (gH2AX) (Shiloh, 2003) and Brca1 to promote DNA damage repair and phosphorylation/stabilization of p53. This leads to either cellcycle arrest (Shiloh, 2003) allowing time to repair DNA damage, or to apoptosis, if the damage is too severe to be repaired.
It has been shown recently that ATM functions in a tumor surveillance system. Ataxia telangiectasia mutated protein signaling contributes to oncogenemediated activation of p14 ARF -p53 (Li et al., 2004) . Oncogene-driven abnormal cell-cycle progression was found to activate ATM in precancerous lesions of the lung and bladder and attenuation of this ATM surveillance system facilitates cancer development (Bartkova et al., 2005; Gorgoulis et al., 2005) . In breast cancer, phosporylation of Chk2 at the ATM phosphorylation site, Thr68, was detected in the absence of irradiation (DiTullio et al., 2002) .
Therefore, we sought to determine whether ATM and p53 play a role in Bcl-2-associated tumor suppression using MCF7 breast cancer cell line as a model system. Surprisingly, we found that MCF7 breast cancer cells express Bcl-2 heterogeneously, with a substantial portion of cells being Bcl-2 negative. These cells generally proliferate faster than those that are Bcl-2 positive. Enforced expression of Bcl-2, in Bcl-2 negative MCF7 cells, induced ATM activation, which was evidenced by increased ATM Ser1981 phosphorylation, phosphorylation of ATM substrate p53Ser15, Chk2Thr68 and H2AXSer139. Attenuation of ATM and p53 function by using an ATM-specific RNAi and a dominantnegative mutant p53 reduced the growth inhibition imposed on MCF7 cell by Bcl-2. Taken together, our data provide evidence for the existence of an ATMdependent surveillance system for Bcl-2 regulation.
Results

Expression of Bcl-2 inhibits MCF7 cell growth
Although the antiapoptotic functions of Bcl-2 are relatively well studied, the mechanisms responsible for Bcl-2-mediated inhibition of cell proliferation remain elusive. Additionally, the observations that reduced Bcl-2 expression correlates with an unfavorable prognosis for breast cancer patients (Chang et al., 2003) are also not well understood. To investigate Bcl-2-associated tumor suppression, we ectopically expressed Bcl-2 in MCF7 breast cancer cells. Compared to an empty vector control, Bcl-2 overexpression clearly inhibited MCF7 cell proliferation (Figure 1 ). This was not due to a lower transfection efficiency for Bcl-2 than for pcDNA3 (vector), as co-transfection of a green fluorescent protein (GFP) vector (without G418 selection marker) with pcDNA3 or Bcl-2 at the ratio of 1:5 (GFP:pcDNA3 or Bcl-2) showed a comparable number of GFP-positive cells 24 h after transfection (data not shown). To confirm this Bcl-2-associated growth inhibition, we examined whether the levels of endogenous Bcl-2 expression correlated with the rate of MCF7 cell proliferation. To address this issue, we hypothesized that MCF7 cells may express Bcl-2 heterogeneously, which would mirror the heterogeneous Bcl-2 expression Figure 1 Enforced Bcl-2 expression inhibits MCF7 cell growth. MCF7 cells were seeded at 5 Â 10 5 in six-well plates 1 day before mock transfected and transfected with 0.4 mg green fluorescent protein (GFP) plasmid plus 2 mg of pcDNA3 (vector) or plus Bcl-2 plasmid using lipofectaminet2000 (Invitrogen). The GFP plasmid contains no selection marker. Two days after transfection, cells were selected in G418 (1.5 mg/ml) containing medium for 2 weeks and cell colonies were stained with 0.1% crystal violet. The experiments were repeated twice. observed in breast cancer patients (Jager et al., 2002) . Accordingly, we have selected 55 MCF7 single-cell clones from a pool of early passage MCF7 cell population obtained from American Type Culture Collection. Western blot analysis of Bcl-2 expression in the single-cell clones revealed that Bcl-2 expression is highly heterogeneous and ranged from abundant (easily detectable) to non-detectable (Figure 2a) . Furthermore, RNA protection analysis of three Bcl-2-positive and three Bcl-2-negative single-cell clones detected Bcl-2 transcript only in Bcl-2-positive cells, whereas Bcl-xL, Bax, Bak and Bik were expressed at comparable levels in both Bcl-2-positive and -negative cells (data not shown). This reveals that lack of the Bcl-2 protein in Bcl-2-negative MCF7 cells is due to inability to produce Bcl-2 transcripts. Among the 55 single-cell clones we isolated, 19 (34.5%) were Bcl-2 negative ( Table 1 ). Loss of Bcl-2 protein expression was specific as all of the single-cell clones expressed Bcl-xL uniformly (data not shown). The heterogeneous nature of Bcl-2 expression is also specific for MCF7 cells as 27 single-cell Jurkat clones expressed Bcl-2 at comparable levels (Table 1) .
To exclude the possibility that the Bcl-2-negative MCF7 cells were resulted from the process of single-cell cloning, which may for some unknown reasons induce Bcl-2 promoter methylation or some other changes in chromatin structure, we re-selected single-cell clones from two Bcl-2-positive (clones 5 and 30), and two Bcl-2-negative single-cell populations (clones 2 and 26). All the 27 single-cell clones derived from Bcl-2-positive clones 5 and 30, respectively, expressed the same levels of Bcl-2 as the parental cells (data not shown), whereas all 26 single-cell clones obtained from Bcl-2-negative Figure 2 High levels of Bcl-2 protein reduce MCF7 cell proliferation. (a) MCF7 single-cell clones were generated (Materials and methods) and analysed for their Bcl-2 expression by Western blot using an anti-Bcl-2 antibody. Actin was used as a loading control. (b) 0.7 Â 10 5 cells from three Bcl-2-negative (2, 17, 26) and five Bcl-2-positive (5, 24, 27, 30, 31) MCF7 single-cell clones were seeded in 60 mm dishes in triplicates. Cell number was counted daily. The experiments were repeated twice and data from three independent experiments were analysed and graphed. (c) 5 Â 10 5 Bcl-2-negative clone 26 MCF7 cells were seeded in 100 mm tissue culture plates, untransfected (blank), and transfected with an empty vector or Bcl-2 or p14 ARF plasmid as indicated. Transfected cells were selected in G418 for 2 weeks. Surviving cell colonies were stained with 0.1% crystal violet. Experiments were repeated twice. The same results were obtained using Bcl-2-negative clone 2 and clone 19 MCF7 cells (data not shown). (d) Bcl-2-negative clone 2 MCF7 cells were transfected with an empty vector or Bcl-2 plasmid. Stably transfected single-cell clones were selected and their Bcl-2 expression was confirmed by Western blot (data not shown). 10 4 of the vector transfected and Bcl-2-transfected cells at very early passages after their construction were seeded in six-well plates in triplicates. Cell number was determined every 2 days. Experiments were repeated 4 times and data from five experiments were combined and graphed. Bcl-2 is expressed heterogeneously in the pool MCF7 population.
b Single-cell clones subjected to a second round selection for single-cell clones.
Bcl-2 activates ATM in MCF-7 cells J Zhang et al clones 2 and 26, respectively, were Bcl-2 negative (Table 1) . Taken together, the above observations clearly show that original MCF7 cell line contains cells that express the Bcl-2 protein in a highly variable fashion.
Having shown MCF7 cells express Bcl-2 heterogeneously, we examined whether the levels of Bcl-2 expression correlated with the rate of cellular proliferation. We determined the growth kinetics of three Bcl-2-negative single-cell clones (2, 17 and 26) and five Bcl-2-positive single-cell clones (5, 24, 27, 30 and 31), which express comparable levels of Bcl-2 (data not shown). The Bcl-2-positive single-cell clones proliferated slower than Bcl-2 negative single-cell clones, with the exception of clone 5 (Figure 2b ). Bcl-2-negative clone 19 cells proliferated at a comparable rate as those of the clones 2 and 26 (data not shown). To confirm that the Bcl-2 protein contributes, at least in part, to the slower growth kinetics observed for Bcl-2-positive cells, we re-introduced Bcl-2 protein into Bcl-2-negative cells ( Figure 2c ). Expression of Bcl-2 in clone 26 (Figure 2c ), 19 and 2 cells (data not shown) inhibited colony formation at a magnitude comparable to expression of p14 ARF . Furthermore, analysis of the growth rates of three Bcl-2 stable single-cell clones derived from Bcl-2-negative clone 2 showed that these cells proliferated slower than cells transfected with an empty vector ( Figure 2d ). These three stable lines expressed the same level of Bcl-2 (data not shown).
p53 function contributes to Bcl-2-mediated growth inhibition of MCF7 cells Because of its strong antiapoptotic function of Bcl-2, we reasoned that one possible explanation for the Bcl-2-associated inhibition of MCF7 cell proliferation might be the activation of a putative Bcl-2 surveillance system. As p53 plays an important role in the surveillance of oncogenic activity via p14 ARF -dependent and independent pathways (de Stanchina et al., 1998; Zindy et al., 1998) , we examined whether p53 is involved in Bcl-2-mediated inhibition of MCF7 cell proliferation. Western blot analysis revealed that the p53 protein was more abundant in Bcl-2-positive cells of clones 27, 24 and 30 than in the Bcl-2-negative cells of clones 2 and 26 ( Figure 3a) . However, Bcl-2-negative clone 17 cells contained more p53 protein than the Bcl-2-positive cells of clones 5 and 31 (Figure 3a) . Thus, whereas these results indicate that Bcl-2 overexpression may stabilize p53, other factors must also play a role in the regulation of p53 protein abundance in MCF7 cells.
To examine directly whether expression of Bcl-2 stabilizes p53, we expressed Bcl-2 in the Bcl-2-negative clone 2 cells. Transfected cells were selected in G418 for approximately 2 weeks and then examined for expression of Bcl-2 and p53 at this early passage. As expected, Bcl-2 was specifically detected in Bcl-2-transfected cells (Figure 3b, upper panel) . Interestingly, there was substantially more p53 protein in Bcl-2-transfected cells than in empty vector transfected cells (Figure 3b, upper panel) . Furthermore, consistent with the fact that stress increases p53 protein abundance by stabilizing the protein, p53 protein's half-life was extended to more than 2 h in Bcl-2-transfected cells compared to a half-life of less than 30 min in the parental and vector transfected cells (Figure 3b , bottom panel). Again, the basal level of p53 protein (before CHX treatment) is higher in Bcl-2-transfected cells than in parental and an empty vector transfected cells (Figure 3b , bottom panel). This was not specific for the clone 2 cells, as similar results were obtained after transfection of clones 19 and 26, Bcl-2-negative clone 2 MCF7 cells were transfected with vector (À) or Bcl-2, selected in G418 for 2 weeks, and analysed immediately for Bcl-2, p53 and actin expression by Western blot analysis using specific antibodies (upper panel). Very early passage cells from these transfected population of cells (vector and Bcl-2-transfected) were pooled. These pooled transfectants and the parental cell (Bcl-2-negative clone 2 cells) were incubated with CHX (5 mg/ml) for the indicated periods of time. The expression of p53 protein and actin was determined by Western blot using specific-antibodies. The same data were obtained using Bcl-2-negative clone 19 and 26 cells (data not shown). (c) Bcl-2-negative clone 26 MCF7 cells were transfected with an empty vector or p53175H (inset) and selected in G418 to establish stable lines. The cells were then transfected with a second empty vector, Bcl-2 and p14 ARF and cultured in the presence of puromycin (0.5 mg/ml) for approximately 2 weeks. Surviving cell colonies were stained with 0.1% crystal violet. Approximately 200 colonies were formed in empty vector transfected cells (data not shown). Experiments were repeated twice. The colony numbers of Bcl-2 and p14 ARF -transfected cells were normalized to the number of clones on the empty vector transfected plates.
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Bcl-2-negative cells, with a Bcl-2 expression vector (data not shown). Collectively, these results demonstrate that ectopically expressed Bcl-2 stabilizes p53 protein.
To examine whether p53 function contributes to Bcl-2-mediated inhibition of MCF7 cell proliferation, we attenuated endogenous p53 function by the expression of a dominant-negative p53 mutant, p53175H, in Bcl-2-negative clone 26 MCF7 cells. The increased p53 protein in p53175H-transfected cells indicates the expression of the mutant protein (Figure 3c, inset) , as p53175H does not stabilize endogenous p53. Furthermore, we detected no upregulation of p21 CIP1 in p53175H-transfected cells (data not shown), which would be expected if endogenous p53 was stabilized. We then determined the effects of p53175H on Bcl-2 associated growth inhibition on MCF7 cells. Compared with an empty vector control, expression of p53175H did not affect p14 ARF -mediated growth inhibition, but partially rescued Bcl-2-associated inhibition of colony formation (Figure 3c ). The same results were also obtained from Bcl-2-negative clones 2 and 19 (data not shown). Taken together, these data reveal an important role of p53 function in facilitating the inhibition of MCF7 cell proliferation imposed by Bcl-2.
Expression of Bcl-2 activates ataxia telangiectasia mutated protein Phosphorylation of p53pSer15 is one of the posttranslational modifications involved in stress-induced p53 stabilization. To determine whether Bcl-2 expression induces p53pSer15, we transiently expressed Bcl-2 in Bcl-2-negative clone 19 MCF7 cells. Double immnunofluorescent staining revealed the coexistence of nuclear p53pSer15 with ectopic Bcl-2 ( Figure 4a , the p53pS15 panel). Transfection of the cells with a vector (pcDNA3) did not produce p53pSer15 (data not shown). Approximately 50% of cells expressing ectopic Bcl-2 displayed p53pSer15 (Figure 4b ). In keeping with this observation, Western blot confirmed that Bcl-2 weakly induces p53pSer15 ( Figure 5 ). This suggests that p53 may contribute partially to Bcl-2-mediated growth inhibition of MCF7 cells, consistent with the observation that p53175H only partially releases MCF7 cells from Bcl-2-mediated growth inhibition (Figure 3c) .
One of the kinases that phosphorylates p53Ser15 is ATM (Shiloh, 2003) . We have shown that ATM contributes to the tumor surveillance function of the p14 ARF -p53 system (Li et al., 2004) , suggesting the candidacy of ATM in producing p53pSer15 in response to the Bcl-2 signal. Consistent with this hypothesis, we were able to demonstrate that re-expression of Bcl-2 in clone 19 MCF7 cells resulted in autophosphorylation of serine 1981 of ATM (ATMpSer1981) (Figure 4a (ATMpS1981 panel) and 5). Phosphorylation of Ser1981 activates ATM (Bakkenist and Kastan, 2003) . More than 70% of ectopic Bcl-2-positive cells express ATMpSer1981 (Figure 4b ), suggesting ATM activation being a dominant event induced by ectopic Bcl-2. In contrast, neither overexpression of Bcl-2 in clone 22 MCF7 cells (Bcl-2-positive) nor transfection of clone 19 cells (Bcl-2-negative) with pcDNA3 led to ATMpSer1981 (data not shown). To further confirm the ATM activation, we have examined the phosphorylation of Thr68 of Chk2 (Chk2pThr68), a well-known ATM substrate (Shiloh, 2003) . Bcl-2 clearly induces Chk2pThr68 foci (Figure 4a) , which was not observed in pcDNA3-transfected cells (data not shown). More than 70% of ectopic Bcl-2-positive cells clearly contain Chk2pThr68 foci (Figure 4b) . These results agree with the fact that Bcl-2 activates ATM (Figures 4 and 5) .
We have further determined the possible mechanism responsible for Bcl-2-mediated ATM activation. The fact that ectopic Bcl-2 signals do not colocalize with those of ATMpSer1981 (Figure 4a ) suggests that Bcl-2 does not directly activate ATM. As Bcl-2 induces ATMpSer1981 nuclear foci (Figure 4a ), we hypothesized that Bcl-2 may induce DSBs, which lead to ATM activation. Consistent with this prediction, we were able to detect gH2AX nuclear foci (Figure 4a ), which binds to DSBs (Paull et al., 2000) . However, only 40% of cells expressing ectopic Bcl-2 display gH2AX (Figure 4b ) (see Discussion for details), which correlates with the slightly increased level of gH2AX in Bcl-2-transfected cells ( Figure 5 ).
Ataxia telangiectasia mutated protein function contributes to Bcl-2-induced inhibition of MCF7 cell proliferation
To examine the functional role of ATM activation in Bcl-2-mediated inhibition of MCF7 cell proliferation, we downregulated ATM in Bcl-2-negative clone 19 cells using an ATM-specific small interfering RNA (ATMRNAi). Reduction of ATM expression was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting (Figure 6a ). Furthermore, etoposide-induced phosporylation of p53Ser15, a process that depends on ATM (Tang et al., 2002; Li et al., 2004) , was substantially reduced (Figure 6b ). As expected, transfection of Bcl-2 into the control RNAi (CtrlRNAi) cells induced ATMpSer1981 (Figure 6c , upper panel) and this was abolished in ATMRNAi cells (Figure 6c, bottom panel) . Collectively, these data demonstrate the successful downregulation of ATM.
We then investigated the contribution of ATM to Bcl-2-induced p53pSer15 and growth inhibition of MCF7 cells. Bcl-2-induced p53pSer15 (Figure 7a ) and Bcl-2-mediated inhibition of MCF7 cell growth ( Figure 7b ) were dramatically reduced in ATMRNAi-treated cells, compared to CtrlRNAi-treated cells. Taken together, these observations demonstrate that ATM functions in reducing the proliferation of cells harboring Bcl-2 overexpression.
Discussion
Tumorigenic activity due to Bcl-2 overexpression is well documented and largely attributed to its antiapoptotic function. Paradoxically, high levels of Bcl-2 are also associated with delayed tumor progression, especially in breast cancer. Bcl-2 overexpression was found to Bcl-2 activates ATM in MCF-7 cells J Zhang et al associate with slower proliferation, high histological grade of differentiation, smaller tumor size and earlier stages of breast cancer development (Gee et al., 1994; Joensuu et al., 1994; Silvestrini et al., 1994; Daidone et al., 1999; Le et al., 1999) . In several independent studies performed between 1995 and 2003, out of more than 1000 patients with stage I breast cancer who had been subjected to local-regional treatment, patients with Bcl-2-positive tumors were associated with lower relapse rates and increased overall survival during a 4-10 years of follow-up period (Silvestrini et al., 1994; Hellemans et al., 1995; Lipponen et al., 1995; Charpin et al., 1998; Daidone et al., 1999; Jager et al., 2002) .
Consistent with these clinical observations, we have found that MCF7 cells express the Bcl-2 protein heterogeneously, with over 30% of cells being Bcl-2-negative. However, as Bcl-2-positive cells have a growth disadvantage in the process of single cell cloning due to their lower rates of proliferation, the actual portion of Bcl-2-negative cells in a pooled MCF7 population may be somewhat less than 34.5% (Table 1 ). The Bcl-2 protein in Bcl-2-negative MCF7 cells may be downregulated by DNA methylation or other types of chromatin modification, as these cells did not express Bcl-2 transcripts and despite the fact that Southern blot analysis of EcoR1 digested genomic DNA revealed no Figure 4 Expression of Bcl-2 activates the ataxia-telangiectasia mutated protein (ATM) pathway. (a) Bcl-2-negative clone 19 MCF7 cells were transiently transfected with Bcl-2 for 48 h, followed by two-color immunofluorescent staining for Bcl-2 (green) and gH2AX (red), Ser15 phosphorylated p53 (p53pSer15) (red), Thr68 phosphorylated Chk2 (Chk2pThr68) (red), and Ser1981 phosphorylaed ATM (ATMpSer1981) (red). Nuclei were counter-stained with 4 0 , 6 0 -diamidino-2-phenylindol (DAPI) (blue). (b) More than 200 Bcl-2-positive cells were counted in 4-5 randomly selected fields. The gH2AX, p53pSer15, chk2pThr68 and ATMpSer1981-positive nuclei in Bcl-2-positive cells were calculated and expressed as % of Bcl-2-positive cells.
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J Zhang et al difference between the genomic hybridization patterns of Bcl-2-positive and -negative MCF7 cells, suggesting the BCL-2 gene is intact (data not shown). The fact that the Bcl-2-negative cells generally proliferate faster than Bcl-2-positive cells is also consistent with clinical observations of their respective primary breast cancers. Although upregulation of p27 KIP1 (a Cdk inhibitor) has been reported to contribute to Bcl-2-induced inhibition of cell-cycle entry in lymphocytes and other cells (Pietenpol et al., 1994; Brady et al., 1996; Linette et al., 1996; Mazel et al., 1996; O'Reilly et al., 1996; Vairo et al., 1996; Huang et al., 1997) , this is not the case for MCF7 cells. The p27 KIP1 protein was expressed homogeneously in all MCF7 single-cell clones regardless their levels of Bcl-2 expression (data not shown). Furthermore, ectopic expression of Bcl-2 in several Bcl-2-negative single-cell clones did not lead to the upregulation of the p27 KIP1 protein (data not shown).
We provide evidence that the Bcl-2-associated 'antitumorigenic' function in breast cancer may be mediated by the activation of an ATM-dependent tumor surveillance system. Ectopic Bcl-2 activates ATM that phosphorylates p53Ser15 and leads to p53 stabilization. Reduction of ATM using RNAi approach abolishes Bcl-2-induced p53pSer15 (Figure 7a ) and growth inhibition of MCF7 cells (Figure 7b ). Attenuation of p53 function by ectopic expression of p53175H partially releases this inhibition (Figure 3c ). This partial release of growth inhibition might be due to incomplete inhibition of endogenous p53 function by p53175H, as ionizing radiation still arrested p53175H cells in G1 and G2/M phases (data not shown), and ionizing radiation-induced G1 arrest requires p53 function (Ko and Prives, 1996) . It is also possible that Bcl-2 may also inhibit MCF7 cell proliferation via a p53-independent pathway. This is supported by the observations that Bcl-2 activates ATM (Figures 4 and 5) and that ATM may predominantly phosphorylate Chk2 than p53, as approximately 75% of ectopic Bcl-2 cells contain Chk2pThr68 versus 50% of p53pSer15 cells in ectopic Bcl-2-positive cells (Figure 4b ). Our research thus indicates an ATM-p53 surveillance system for modulating the effects of Bcl-2 overexpression. This is further supported by our observation that expression of Bcl-2 in Bcl-2-positive clone 22 cells did not result in ATM activation and inhibition of cell proliferation (data not shown).
The possible existence of an ATM-dependent surveillance system for Bcl-2 in breast cancer development is consistent with recent findings showing that activation of ATM is an early event in lung and bladder cancer initiation, and that attenuation of ATM function promotes the cancer progression (Bartkova et al., 2005; Gorgoulis et al., 2005) . The proposed mechanism for ATM activation in lung and bladder tumorigenesis is DNA replication stress imposed by abnormal cell cycle progression, which produces DNA damage and therefore activation of ATM. Bcl-2-mediated ATM activation may also involve DNA damage or genomic instability, as Bcl-2 overexpression suppresses mismatch repair (Youn et al., 2005) . Consistent with this possibility, we found that Bcl-2 induces gH2AX nuclear foci (Figure 4) , suggesting the existence of DSBs. The fact that >70% of Bcl-2-positive cells are ATMpSer1981 positive versus 40% of gH2AX-positive cells in ectopic Bcl-2-positive cells (Figure 4b ) may suggest that gH2AX precedes Bcl-2-induced ATMpSer1981. However, the possibility that other mechanisms besides DSBs Figure 5 Ectopic Bcl-2 induces ataxia-telangiectasia mutated protein (ATM)pSer1981, gH2AX and p53pSer15. Bcl-2-negative clone 19 MCF7 cells were infected with an empty vector (vector) or Bcl-2 retrovirus for 2 days. Cell lysate was then prepared and analysed for the expression of ATMpSer1981, p53pSer15, gH2AX and Bcl-2 by Western blot using specific antibodies. ATR (ATMand rad3-related), H2AX and actin were used as loading controls for ATMpSer1981, gH2AX and p53pSer15, respectively.
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The concept of an ATM-mediated surveillance system also explains why high levels of Bcl-2 do not always predict favorable outcomes for breast cancer patients (van Slooten et al., 1996) , as this may be attributed to the inactivation or attenuation of the surveillance function. Based on this notion, a combination of Bcl-2 levels in association with ATM activation status may improve the prognostic predictions for breast cancer patients. As Bcl-2 is reported to suppress c-Myc-induced liver cancer formation, knocking out ATM function should release the inhibition.
Materials and methods
Cell lines and expression vectors
Jurkat cells were cultured in RPMI1640, 10% of fetal calf serum (FCS). MCF7 cell line was obtained from ATCC and cultured in Dulbecco's modified Eagle's medium supplemented with 10% FCS. MCF7 single-cell clones were generated by limited dilution. Jurkat single-cell clones were produced by cell sorting using a flow cytometer. Expression vectors used in this investigation were pcDNA3.0, pcDNA3.1 (hygromycin selection marker). Human Bcl-2 was inserted in pcDNA3 and pcDNA3.1. The expression of a dominant negative p53 mutant p53175H and p14 ARF was carried out as previously described (Li et al., 2004) .
Generation of stable cell lines
Vector, Bcl-2 and p53175H stable lines were generated by transfection of MCF7 cells with pcDNA3, pcDNA3/Bcl-2 and pcDNA3/p53175H, followed by selection of transfected cells with Geneticin (G418, GIBCO BRL, Burlinton, Ontario, Canada) at 1 mg/ml. Single-cell clones were produced by limited dilution.
Cell lysis and Western blot
Cells were lysed in a buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM ethyleneglycol tetraacetate, 1% Triton X-100, 25 mM sodium pyrophosphate, 1 mM NaF, 1 mM b-glycerophosphate, 0.1 mM ATMRNAi and CtrlRNAi (À) cells were treated with 100 mM etoposide as indicated for 3 h, followed by analysis for p53pSer15 and actin by Western blot using specific antibodies. (c) CtrlRNAi and ATMRNAi cells were transiently transfected with Bcl-2 for 48 h and double immunofluorescently stained for Bcl-2 (green) and ATMpSer1981 (red). Nuclei were counter-stained with 4 0 , 6 0 -diamidino-2-phenylindol (DAPI) (blue).
Bcl-2 activates ATM in MCF-7 cells J Zhang et al sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin and 10 mg/ml aprotinin. Fifty micrograms of total cell lysate was separated on sodium dodecyl sulfatepolyacrylamide gel electrophoresis gel and transferred onto Immobilon-P membranes (Millipore, Etobicoke, Ontario, Canada). Membranes were blocked with 5% skim milk and then incubated with the indicated antibodies at room temperature for 1 h. Signals were detected using an enhanced chemiluminescence Western Blotting Kit (Amersham, Quebec, Canada). Primary antibodies and concentrations used were: anti-p53 (FL-353 at 1 mg/ml, Santa Cruz, California, USA); anti-Bcl-2 (1 mg/ml, Santa Cruz); anti-Actin (Santa Cruz, 1:1000); anti-Bcl-x L (1 mg/ml, Transduction Laboratories, Mississauga, Ontario, Canada); anti-p27 KIP1 (1 mg/ml, Santa Cruz).
Immunofluorescence
Immunofluorescent staining was performed according to our published procedure (Li et al., 2004) . Briefly, cells were fixed using prechilled (À201C) acetone-methanol for 15 min. The primary antibodies, anti-Bcl-2 (1:50, Santa Cruz), anti-Ser1981 phosphorylated ATM (1:50, Rockland, Gilbertsville, PA, USA), anti-S15 phosphorylated p53 (Cell Signalling, 1 mg/ml), anti-Thr68 phosphorylated Chk2 (Cell Signalling, 1:50), and Assay for p53 protein's half-life The sensitivity of MCF7 cells to cycloheximide (CHX)-induced protein synthesis inhibition was pre-determined. MCF7 cells were cultured for 2 h in [ 35 S]methionine medium supplemented with CHX at 1, 2.5, 5, 10, 15 and 20 mg/ml. It was found that CHX at 5 mg/ml was sufficient to inhibit [ 35 S]methionine incorporation almost completely (data not shown). Cells were subsequently cultured in CHX (5 mg/ml) containing medium for 0.5, 1, 1.5 and 2 h and then examined for p53 protein content by Western blot using an anti-p53 antibody. Actin was used as a loading control.
Downregulation of ataxia telangiectasia-mutated protein by small interference RNA This was carried out as previously described (Li et al., 2004) . The control ATM RNAi fragment (CrtlRNAi) used in these experiments was sense: GATCCCCGCACCAGTCCAGTATT GGCTTCAAGAGAGCCAATACTGGACTGGTGCTTTTTG GAAA and antisense: AGCTTTTCCAAAAAGCACCAGT CCAGTATTGGCTCTCT-TGAAGCCAATACTGGACTGG TGCGGG. The ATM RNAi fragment (ATMRNAi) was sense: GATCCCCTCTCAGCAACAGTGGTTAGTTCAAGAGACT AACCACTGTTGCTGAGATTTTTGGAAA and antisense: AGCTTTTCCAAAAATCTCAGCAACAGTGGTTAGTCTC TTGAACTAACCACTGTTGCTGAGAGGG. Nucleotides bolded and underlined are those of the sense and antisense sequences that will form a hairpin structure upon transcription inside cells. High titer retrovirus was packed and used to infect MCF7 cells.
Reverse transcription-polymerase chain reaction Total RNA was isolated using Trizol (Life Technology, Burlinton, Ontario, Canada) from MCF7CtrlRNAi and MCF7ATMRNAi cells according to the manufacturer's instructions. Reverse transcription (RT) was carried out using a RT kit (Clontech, Palo Alta, CA, USA). Specific primers used for ATM are: 5 0 -TCTTGATAAATGAGCAGTCAGC-3 0 (upper) and 5 0 -ACACGTTCAGCTACTTTGTCG-3 0 (lower); for b-actin are: 5 0 -AACCCCAAGGCCAACCGCGA GAAG-3 0 (upper) and 5 0 -TCATGAGGTAGTCAGTCAG-3 0 (lower). Amplification of actin up to 25 cycles was in the linear range (data not shown). Thus, RT-PCR of ATM and actin was achieved with 30 and 23 cycles, respectively.
Growth curve, colony formation and soft agar assays For growth curves, 10 4 MCF7 cells were seeded in triplicates in six-well plates and cell numbers were counted every 2 days. Experiments were repeated twice. 10 6 or 10 5 MCF7 cells were seeded in 100 mm tissue culture dishes or six-well plates, respectively 1 day earlier and transfected with 10 or 2 mg, respectively, of designed plasmid (vector or Bcl-2 or p14 ARF ) using either FuGENE 6 (Boehringer-Mannheim, Laval, QC, Canada) or lipofectaminet2000 (Invitrogen, Carlsbad, CA, USA). Cells were cultured in the presence of G418 (1 mg/ml) for 2-3 weeks until colonies were formed, that were stained with 0.1% crystal violet.
